GB2098506A - Drug coated materials - Google Patents
Drug coated materials Download PDFInfo
- Publication number
- GB2098506A GB2098506A GB8127345A GB8127345A GB2098506A GB 2098506 A GB2098506 A GB 2098506A GB 8127345 A GB8127345 A GB 8127345A GB 8127345 A GB8127345 A GB 8127345A GB 2098506 A GB2098506 A GB 2098506A
- Authority
- GB
- United Kingdom
- Prior art keywords
- implant
- transplant
- chondroitin sulfate
- active
- drug
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229940079593 drug Drugs 0.000 title claims description 29
- 239000003814 drug Substances 0.000 title claims description 29
- 239000000463 material Substances 0.000 title description 7
- 239000007943 implant Substances 0.000 claims abstract description 30
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 claims abstract description 10
- 229920001287 Chondroitin sulfate Polymers 0.000 claims abstract description 10
- 229940059329 chondroitin sulfate Drugs 0.000 claims abstract description 10
- KXKPYJOVDUMHGS-OSRGNVMNSA-N chondroitin sulfate Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](OS(O)(=O)=O)[C@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](C(O)=O)O1 KXKPYJOVDUMHGS-OSRGNVMNSA-N 0.000 claims abstract description 7
- 230000000399 orthopedic effect Effects 0.000 claims abstract description 4
- 239000002674 ointment Substances 0.000 claims description 4
- 210000001519 tissue Anatomy 0.000 description 18
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 12
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 12
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 10
- 239000000243 solution Substances 0.000 description 10
- 239000002244 precipitate Substances 0.000 description 9
- NUJOXMJBOLGQSY-UHFFFAOYSA-N manganese dioxide Chemical compound O=[Mn]=O NUJOXMJBOLGQSY-UHFFFAOYSA-N 0.000 description 8
- 238000000034 method Methods 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- 238000002054 transplantation Methods 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 239000011248 coating agent Substances 0.000 description 5
- 238000000576 coating method Methods 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 210000000056 organ Anatomy 0.000 description 5
- 238000003756 stirring Methods 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 238000005119 centrifugation Methods 0.000 description 4
- 239000008367 deionised water Substances 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 210000003437 trachea Anatomy 0.000 description 4
- 241000283690 Bos taurus Species 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 229960000583 acetic acid Drugs 0.000 description 3
- 210000000845 cartilage Anatomy 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 239000012362 glacial acetic acid Substances 0.000 description 3
- 210000002216 heart Anatomy 0.000 description 3
- 210000003709 heart valve Anatomy 0.000 description 3
- 238000002513 implantation Methods 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 210000003491 skin Anatomy 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 241000251730 Chondrichthyes Species 0.000 description 2
- 238000013019 agitation Methods 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 239000003925 fat Substances 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 238000005189 flocculation Methods 0.000 description 2
- 230000016615 flocculation Effects 0.000 description 2
- 210000001624 hip Anatomy 0.000 description 2
- 210000004394 hip joint Anatomy 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 230000001050 lubricating effect Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000012286 potassium permanganate Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 230000000717 retained effect Effects 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 230000000451 tissue damage Effects 0.000 description 2
- 231100000827 tissue damage Toxicity 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 206010053567 Coagulopathies Diseases 0.000 description 1
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 108090000526 Papain Proteins 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 206010060932 Postoperative adhesion Diseases 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 206010066902 Surgical failure Diseases 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 1
- 206010052779 Transplant rejections Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000010775 animal oil Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- VSGNNIFQASZAOI-UHFFFAOYSA-L calcium acetate Chemical compound [Ca+2].CC([O-])=O.CC([O-])=O VSGNNIFQASZAOI-UHFFFAOYSA-L 0.000 description 1
- 239000001639 calcium acetate Substances 0.000 description 1
- 229960005147 calcium acetate Drugs 0.000 description 1
- 235000011092 calcium acetate Nutrition 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- YMKDRGPMQRFJGP-UHFFFAOYSA-M cetylpyridinium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCC[N+]1=CC=CC=C1 YMKDRGPMQRFJGP-UHFFFAOYSA-M 0.000 description 1
- 229960001927 cetylpyridinium chloride Drugs 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000035602 clotting Effects 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 239000012050 conventional carrier Substances 0.000 description 1
- 210000004087 cornea Anatomy 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 238000010908 decantation Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 230000007560 devascularization Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 239000003248 enzyme activator Substances 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 210000001503 joint Anatomy 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 210000000629 knee joint Anatomy 0.000 description 1
- 210000002414 leg Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 229940055729 papain Drugs 0.000 description 1
- 235000019834 papain Nutrition 0.000 description 1
- 238000004816 paper chromatography Methods 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 235000019271 petrolatum Nutrition 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 210000001525 retina Anatomy 0.000 description 1
- 239000012047 saturated solution Substances 0.000 description 1
- 238000003307 slaughter Methods 0.000 description 1
- 238000002791 soaking Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 230000007928 solubilization Effects 0.000 description 1
- 238000005063 solubilization Methods 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 239000008227 sterile water for injection Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 239000010936 titanium Substances 0.000 description 1
- 229910052719 titanium Inorganic materials 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L29/00—Materials for catheters, medical tubing, cannulae, or endoscopes or for coating catheters
- A61L29/08—Materials for coatings
- A61L29/085—Macromolecular materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K6/00—Preparations for dentistry
- A61K6/20—Protective coatings for natural or artificial teeth, e.g. sealings, dye coatings or varnish
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/28—Materials for coating prostheses
- A61L27/34—Macromolecular materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L33/00—Antithrombogenic treatment of surgical articles, e.g. sutures, catheters, prostheses, or of articles for the manipulation or conditioning of blood; Materials for such treatment
- A61L33/06—Use of macromolecular materials
- A61L33/08—Polysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
Abstract
A transplant, implant, inanimate prosthetic or orthopedic device. surgical instrument or the like when coated with an effective amount of "active" chondroitin sulfate A and/or "active chondroitin sulfate C to mitigate rejection or failure of a transplant or implant.
Description
SPECIFICATION
Drug coated materials
The use of "active" chondroitin sulfate A and
C, and mixtures of these drugs are known for use in the treatment of a variety of cardiovascular diseases and as preventative therapy for these diseases. These drugs including their method of production are described in Morrison U.S. Patents
Nos. 3,895,106 and 3,895,106 issued July 15,
1975. An improved method for the production of these drugs is disclosed in U.K. Patent Application
No.8025221.
It has now been discovered that "active" chondroitin sulfate A, "active" chondroitin sulfate
C, and mixtures thereof, have a unique and very different therapeutic use. It has been reported in the literature in numerous instances that organ or tissue transplants are subject to rejection by the human host. This problem is also present to a degree in relation to inanimate implants such as tooth implants, hip prosthesis, intraocular implant, heart valve, etc. It is generally believed that the transplant rejection phenomena is associated with the immune system of the body and/or physiologic processes or surgical procedures. The immune system -recognizes the transplanted tissue as foreign and produces antibodies which attack the object foreign to the human host. Surgical failure and physiologic failure may be related to mechanical tissue damage, clotting with decreased blood flow, etc.
Various approaches have been followed in attempting to diminish or eliminate the rejection or failure problem.
We have found that "active" chondroitin sulfate A, "active" chondroitin sulfate C, or admixtures of the drugs seems to significantly reduce the tendency of the human body to reject transplants and increase the acceptance of implants.
The rejection of implants is due to additional factors including direct mechanical injury to adjacent tissues, devascularization of tissues with resultant poor oxygen supply, tissue unacceptance of the foreign body whether due to direct lack of adherence of adjacent cells, lack of proper electrostatic forces, or poor regeneration of tissues.
The coating of the foreign bodies and/or host treatment with the drugs of this invention reduces rejection and may result in better acceptance of the implant by the surrounding tissues.
It is believed that this development represents a significant advance in this area of therapy.
The coating of surgical instruments will reduce direct tissue damage resulting from contact with these instruments. Likewise, the coating of indweliing catheters or needles will reduce mechanical damage to contiguous endothelial cells within the vascular channel.
It is believed that this development represents a significant advance in this area of therapy.
The present invention provides a transplant, implant, inanimate prosthetic or orthopedic device, surgical instrument or the like when coated with an effective amount of "active" chondroitin sulfate A and/or "active" chondroitin sulfate C to mitigate rejection or failure of a transplant or implant.
The use of an effective amount of "active" chondroitin sulfate A and/or "active"chondroitin sulfate C mitigates rejection or failure of a transplant or implant in the transplantation or implantation into the body of tissue or organs from the same or another human or animal.
The invention provides a new and improved means for combating the problem of rejection, and stimulating and promoting acceptance of both living and inanimate transplants or implants by the human body.
As used herein, the term "transplant" or "transplantation" refers to the grafting of tissue taken from the same or another person. More specifically, it refers to the operation of transplanting or of applying to a part of the body tissues taken from another body or from another part of the same body. This invention covers the full array of such procedures and is particularly used in heart, kidney, lung and skin transplants.
The term "implant" or "implantation" means the placement within the body tissues of a foreign, usually inanimate substance. A hip joint mechanical heart valve, surgical staples and intraocular lens are examples. The implanting of pig tissue into humans for heart valve reconstruction is also contemplated by this invention, whether regarded as an implant or a transplant. The "implant" need not be permanent.
Thus, the term "implant" herein is broader than in the conventional sense and includes the use of the drugs to coat surgical instruments just prior to their temporary use in the human body. An indwelling catheter or needle can be beneficially coated with the drugs prior to placement into the patient. Likewise, IV tubing, sutures and even surgical instruments. The coating of implants such as titanium rods to act as a bone, and mechanical metal knee and hip joints is of considerable value. As used herein, a "prosthetic" device refers to any artificial substitute for a missing part, as denture, hand, leg or eye.
While not bound by any theory, it is believed that the present invention improves the implantation in inanimate devices by virtue of the fact that the drug has a negative electrical charge and the implants bear a positive surface charge.
The hypothesis is that the drugs lead to the neutralization of the positive charge or create a resultant negative charge which provides for less damage to contiguous cells or tissues. Another likely factor is the lubricating properties of the drugs which seem to increase compatability of the implant with the surrounding living tissues and prevents direct mechanical cell damage. The lubricating properties of the drugs via direct application to intraperitoneal surfaces or structures at the time of abdominal surgical procedures may reduce the occurrence of postoperative adhesions.
These and other objects and advantages of this invention will be apparent from the more detailed description which follows.
Description of the preferred embodiments
The present invention is applicable to the transplantation, human-to-human, animal-tohuman, of all organs and tissues including kidney, heart, lungs, skin, etc. It also appears to be useful in cases of re-attachment of tissues or organs such as in cases requiring the re-attachment of the cornea or retina.
The drug can be administered beginning three to four days prior to the transplantation or implant and can usefully be continued for weeks, months, or even years thereafter. In any case, the drug would be administered essentially concurrently with transplantation. The mode of administration is by injectible aqueous solution, orally, or the like.
The administration in the case of major organ transplant is intra-peritoneally, intravenously or orally or powder, ointment, eye drops, as an aqueous solution. The dosage would be an effective amount on the order of 0.1 to 10 or more grams per 24 hour period.
It is also beneficial to soak, infuse, coat or incubate the transplant or implant, that is, the skin, heart, kidney or lung or artificial, synthetic devices with the drug just before transplantation or implant in the human recipient.
In the case of inanimate implants for the eye or joints such as intraocular lens, tooth implant, knee implant, orthopedic plates or pins, hip prosthesis, the inanimate transplant or implant, can be beneficially coated with the drug just prior to placement in the human body, and fortified periodically by local applications or injections and the like of the "active" drug.
The soaking or coating procedures just described are usually in addition to the more protracted systemic administration of the drug earlier described hereinabove. The solution used to coat is a 1 to 30% by weight of a physiologically compatible, normally aqueous, solution of the drug. The drug can be applied to the eye in drop form. The drugs can also be combined with conventional carriers to form a viscous ointment and coated onto a skin transplant to mitigate rejection. The drugs used in the practice of this invention are prepared as follows:
Example 1
On hundred pounds of trimmed bovine trachea was chopped into 1 inch square segments and added to about 50 gallons of deionized water in a tank. The pH was adjusted to about 4.5 by addition of approximately 400 ml of glacial acetic acid.The resulting suspension was agitated while the contents of the tank was raised to about 500 C. One and one-quarter pounds of pepsin was added and the agitation continued for 30 minutes.
Another 50 gallons of de-ionized water was added to the tank and mild stirring continued for 12 hours at 500C until the tracheal cartilage is freed of connective tissue. The temperature of the suspension is then raised to 800C and a fat layer formed on the top of the liquid. The digestion liquor was drained off through basket centrifuge and discarded.
The remaining solids were twice washed with 50 gallons of hot water (60-800C). A sodium hydroxide solution was prepared by adding 1.5
Ibs. of NaOH to 5 gallons of de-ionized water in a tank. The twice washed solids were added to the sodium hydroxide solution, and the volume adjusted with de-ionized water to 12 gallons and the pH to 9-10. The contents of the tank was agitated for 12 hours at 37 or. The pH was then adjusted to 6.5 with glacial acetic acid. The liquid was heated to boiling and then permitted to cool.
The liquid was filtered through a basket centrifuge and the filtrate collected and retained. To the retained filtrate was added 1.5 pounds of cetyl pyridinium chloride followed by stirring for 30 minutes. The liquid was allowed to stand for 16 hours. A precipitate from the supernatant was decanted and the precipitate collected by continuous centrifugation in a Sharples centrifuge. The collected precipitate was in 5 gallons of 0.5N sodium hydroxide. Ten gallons of methanol was added and allowed to stand for 12 hours at room temperature. The precipitate formed was again collected by continuous centrifugation and washed with 5 gallons of methanol. The precipitate was dissolved in two gallons distilled water, the pH adjusted to 7.0 with glacial acetic acid and 1/4 pound of sodium chloride was added, followed by stirring.Four gallons of methanol was added and agitation was carried out for 1 5 minutes. After standing for 12 hours at room temperature, a precipitate had formed which was collected by centrifugation.
The precipitate was dried under vacuum. Analysis showed the precipitate to be essentially CSA. The material manifested a prolongation of plasma thrombus formation time 6 to 12 hours after administration in rabbits as described by the
Chandler loop method of over 80%.
A sterile solution suitable for intravenous injection or local applicable is obtained by dissolving 125 mg. of the drug in 2.5 ml of USP sterile water for injection. If necessary, the solution can be finally sterilized by passing it through a sterilizing membrane filter. When donor human skin was soaked for five minutes in this solution and applied to an area of third degree burn, the rejection was reduced.
An ointment containing the drugs is prepared by adding from about 1 to 30% by weight of the drug to a vehicle or carrier which is normally viscous such as petroleum jelly or made viscous by the addition of emulsifiers or thickeners to water. The vehicle or carrier are usually composed of various mixtures of fats, waxes, animal and vegetable oils, and solid or liquid hydrocarbons.
Example2
One starting material for the preparation of active chondroitin sulfate A is bovine trachea. This material is obtained from the slaughter houses as soon as possible after the animals are slaughtered. It is then frozen until processed. In processing, it is trimmed free of tissue and finely ground. This ground tissue is defatted with five parts of acetone. Two extractions are made to reduce the fat content to approximately 1 percent or less. The defatted material is dried and reground. A 5 percent solution of the latter is made up in a 0.1 M calcium acetate buffer containing 1 percent papain plus 0.005M cystein hydrochloride and 0.005M disodium versenate as enzyme activators. The entire mixture is maintained at 620C+30C for 24 to 30 hours with gentle stirring. Approximately 85 to 95 percent solubilization of the trachea is obtained.This supernatant is decanted and is precipitated with two volumes of acetone. The acetone supernatant is decanted. The remaining precipitated material is dissolved in isotonic saline to make a solution of 3-5 percent. To the latter is added a saturated solution of potassium permanganate in 2 to 5 ml.
portions with constant stirring, adding each portion until the purple color has been totally discharged. Depending on the various raw materials started with, this may take anywhere from 50 to 200 ml. of potassium permanganate solution per 6 Ibs. of starting raw material. When at the interval between addition and discharge, the color becomes long (sic) (more than 5 minutes), no further permanganate is added. The solution is then allowed to stand overnight to permit flocculation of the manganese dioxide and completion of any reactions. The manganese dioxide is removed either by centrifugation or filtration through a coarse filter paper. The manganese dioxide cake is washed with additional isotonic saline. In some cases the addition of a small amount of formaldehyde or methanol will cause flocculation of manganese dioxide which is then precipitated with one volume of acetone.The resultant oily precipitate is collected by decantation, the solvent evaporated or the cake dissolved in a minimum amount of water and the final product obtained by lyophilization. It appears on paper chromatography to be essentially pure chondroitin sulfate A. Analysis of the product shows a typical chondroitin sulfate A infra-red spectrophotometric absorption curve. Optical rotation determination gives values of (a)4=--240; nitrogen content, 3.3%.
Example 3
One starting material for the preparation of active chondroitin sulfate C is shark cartilage. This material obtained in dry form is ground and defatted with three to five parts acetone. One extraction is usually sufficient. This extracted shark cartilage is then treated as indicated above for the dried bovine trachea after the defatting stage.
The drugs prepared as in Example 2 and 3 are useful in all of the procedures described hereinabove.
Having fully described the invention, it is intended that it be limited only by the lawful scope of the appended claims.
Claims (3)
1. A transplant, implant, inanimate prosthetic or orthopedic device, surgical instrument or the like when coated with an effective amount of "active" chondroitin sulfate A and/or "active" chondroitin sulfate C to mitigate rejection or failure of a transplant or implant.
2. A transplant, implant, device, instrument or the like according to claim 1 which has been coated with sterile IV solution of the drug.
3. A transplant, implant, device, instrument or the like according to claim 1 which has been coated with an ointment of the drug.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US26378881A | 1981-05-14 | 1981-05-14 |
Publications (2)
Publication Number | Publication Date |
---|---|
GB2098506A true GB2098506A (en) | 1982-11-24 |
GB2098506B GB2098506B (en) | 1984-10-03 |
Family
ID=23003232
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
GB8127345A Expired GB2098506B (en) | 1981-05-14 | 1981-09-10 | Drug coated materials |
Country Status (7)
Country | Link |
---|---|
JP (1) | JPS57188522A (en) |
CA (1) | CA1179264A (en) |
DE (1) | DE3144236A1 (en) |
DK (1) | DK70382A (en) |
FR (1) | FR2505656A1 (en) |
GB (1) | GB2098506B (en) |
SE (1) | SE8107352L (en) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0121008A2 (en) * | 1983-03-29 | 1984-10-10 | Marcel E. Nimni | Coating for bioprosthetic device and method of making same |
GB2270861A (en) * | 1992-04-07 | 1994-03-30 | Wilhelm Env Tech Inc | Flue gas conditioning system |
GB2297931A (en) * | 1992-04-07 | 1996-08-21 | Wilhelm Env Tech Inc | Flue gas conditioning system |
EP1129209A2 (en) * | 1998-11-11 | 2001-09-05 | The Board Of Regents Of The University Of Oklahoma | Polymer grafting by polysaccharide synthases |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2037942C2 (en) * | 1970-04-15 | 1982-11-18 | Biomed Research, Inc., 90048 Los Angeles, Calif. | Medicaments containing an "active" chondroitin sulfate as an active ingredient for preventing the occurrence of atherosclerotic lesions and for preventing the occurrence of heart attacks |
US3895106A (en) * | 1970-04-15 | 1975-07-15 | Morrison L M | Novel CSA and CSC for use in man and mammals to inhibit atherosclerosis and the recurrence of cardiovascular incidents in atherosclerotic mammals |
JPS5235710A (en) * | 1975-09-16 | 1977-03-18 | Ulvac Corp | In-material-heat reflection plate device in heating furnaces |
US4302577A (en) * | 1979-10-05 | 1981-11-24 | Biomed Research Inc. | Process for preparing CSA or CSC |
-
1981
- 1981-09-10 GB GB8127345A patent/GB2098506B/en not_active Expired
- 1981-10-13 JP JP56162145A patent/JPS57188522A/en active Pending
- 1981-11-02 CA CA000389215A patent/CA1179264A/en not_active Expired
- 1981-11-06 DE DE19813144236 patent/DE3144236A1/en active Granted
- 1981-12-08 SE SE8107352A patent/SE8107352L/en not_active Application Discontinuation
-
1982
- 1982-02-08 FR FR8201965A patent/FR2505656A1/en active Pending
- 1982-02-17 DK DK70382A patent/DK70382A/en not_active Application Discontinuation
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0121008A2 (en) * | 1983-03-29 | 1984-10-10 | Marcel E. Nimni | Coating for bioprosthetic device and method of making same |
EP0121008A3 (en) * | 1983-03-29 | 1985-03-27 | Marcel E. Nimni | Coating for bioprosthetic device and method of making same |
GB2270861A (en) * | 1992-04-07 | 1994-03-30 | Wilhelm Env Tech Inc | Flue gas conditioning system |
GB2297931A (en) * | 1992-04-07 | 1996-08-21 | Wilhelm Env Tech Inc | Flue gas conditioning system |
GB2297931B (en) * | 1992-04-07 | 1996-10-16 | Wilhelm Env Tech Inc | Flue gas conditioning system |
GB2270861B (en) * | 1992-04-07 | 1996-10-16 | Wilhelm Env Tech Inc | Flue gas conditioning system |
EP1129209A2 (en) * | 1998-11-11 | 2001-09-05 | The Board Of Regents Of The University Of Oklahoma | Polymer grafting by polysaccharide synthases |
EP1129209A4 (en) * | 1998-11-11 | 2004-04-07 | Univ Oklahoma | Polymer grafting by polysaccharide synthases |
Also Published As
Publication number | Publication date |
---|---|
GB2098506B (en) | 1984-10-03 |
DE3144236A1 (en) | 1982-11-25 |
FR2505656A1 (en) | 1982-11-19 |
CA1179264A (en) | 1984-12-11 |
DE3144236C2 (en) | 1987-04-30 |
DK70382A (en) | 1982-11-15 |
SE8107352L (en) | 1982-11-15 |
JPS57188522A (en) | 1982-11-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6949625B2 (en) | Injectable implant of insoluble globin | |
US7709017B2 (en) | Implantable preparations | |
FI92906B (en) | Injectable materials isolated from the placenta for soft tissue augmentation and a method of making the same | |
EP3349814B1 (en) | Non-gelling soluble extracellular matrix with biological activity | |
CN109641082B (en) | Dermis layer for increasing survival rate for transplantation and preparation method thereof | |
CN110339398A (en) | One kind Amvisc containing amino acid and preparation method thereof | |
JP2022027930A (en) | Stem cell filtrate preparation and method for preparing the same | |
RU2721116C2 (en) | Compositions for treating tissue injuries | |
CA1179264A (en) | Condranol for transplants | |
CN100566709C (en) | The injectable implant of insoluble globin | |
RU2433828C1 (en) | Injection heterogenic biopolymer hydrogel for substitutional and regenerative surgery and method of its obtaining | |
KR20010038098A (en) | Calcification-resistant Heparinized Bioprosthetic Tissue Implants And Preparation Thereof | |
KR20220089586A (en) | Multi-functional phamaceutical composition for preventing adhesion | |
CN116549485A (en) | Use of beta-polypeptides or beta-polypeptide polymers for promoting angiogenesis and inhibiting organ fibrosis | |
RU2121323C1 (en) | Solution "keratane c" for treatment of patients with sickness and damage of cornea | |
CN116392642A (en) | Extracellular matrix/glycopeptide hydrogel for heart failure treatment and preparation method thereof | |
Monhian et al. | The role of soft-tissue implants in scar revision | |
JPS6365872A (en) | Injection material for forming bone | |
JP2011501677A5 (en) | ||
Banta | Artificial and transplanted organs and tissues |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PCNP | Patent ceased through non-payment of renewal fee |